Navigation Links
Biogen Idec and Isis Pharmaceuticals Announce Collaboration For Antisense Programs To Treat Neurological Disorders
Date:12/10/2012

WESTON, Mass. and CARLSBAD, Calif., Dec. 10, 2012 /PRNewswire/ -- Biogen Idec (NASDAQ: BIIB) and Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) today announced that they have entered into a global collaboration agreement under which the companies will discover and develop antisense drugs against three undisclosed targets to treat neurological or neuromuscular disorders.  Biogen Idec and Isis are also developing antisense drugs to treat spinal muscular atrophy and myotonic dystrophy type 1 under previously established collaborations. 

"Our latest collaboration with Isis to discover and develop novel targets for the treatment of neurological disorders is a perfect fit within our early-stage research strategy," said Richard Brudnick, vice president and co-head of business development at Biogen Idec. "This will be our third collaboration with Isis, which is reflective of our respect for them as a partner and as a leader in antisense technology. By combining Isis' knowledge with Biogen Idec's expertise as a leader in neurology, we believe this latest discovery collaboration holds great potential for finding novel approaches to treating neurologic diseases."

Under the terms of the agreement, Isis will receive an upfront payment of $30 million and is responsible for the discovery of a lead antisense drug for each of the three undisclosed targets. Isis is eligible to receive substantial development milestone payments to support research and development of each program prior to the exercise by Biogen Idec of its option to license each program.  Biogen Idec has the option to license a drug from each of the three programs through the completion of Phase 2 trials. Isis could receive up to another $200 million in a license fee and regulatory milestone payments per program. In addition
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Biogen Idec and Regulus Therapeutics Form Collaboration to Explore microRNA Biomarkers for Disease Monitoring and Response to Therapy
2. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
3. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
4. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
5. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
6. Icahn Issues Statement Regarding Amylin Pharmaceuticals
7. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
8. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
9. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
10. Jazz Pharmaceuticals Announces First Quarter 2012 Financial Results Conference Call On May 8, 2012
11. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... Aug. 3, 2015 VWR (NASDAQ: ... and solutions, announces the redesign of its global website, ... When visiting the new site, guests will enjoy enhanced ... and vivid images.  Each country site now includes: ... Z product menu; and , the ability to search ...
(Date:8/3/2015)... -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK ) today announced ... Investor Conference Call and webcast at 4:30 p.m., Eastern time, ... cover an update on Merrimack,s progress as well as ... release detailing the information to be discussed on the ... 10. Investors and the general public are invited to ...
(Date:8/3/2015)... and FLORHAM PARK, N.J. , Aug. ... naldemedine met its primary and secondary endpoints in a ... opioid-induced constipation (OIC) in adult patients with chronic non-cancer ... receptor antagonist (PAMORA). This is the third Phase III ... secondary endpoints. Study results showed that a ...
Breaking Medicine Technology:VWR's New Website Redesign Provides Improved Functionality for Customers 2Merrimack Pharmaceuticals Announces Timing of Second Quarter 2015 Investor Conference Call 2Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 4
... , PARSIPPANY, N.J. , Jan. 14 ... the spine market, the company has announced the addition of ... individuals filling these positions bring a deep knowledge of the ... developing strong distribution networks in their respective areas.   , ...
... , , ... Jan. 14 ImproMed, Inc. creators of the Infinity ... home delivery services on behalf of veterinarians, announce the integration ... immediately with the release of v4.5 of Infinity, veterinarians can ...
Cached Medicine Technology:Custom Spine Announces the Expansion of its Sales Management Team 2VetCentric and ImproMed, Inc.(R) Announce One-Click Home Delivery Integration 2VetCentric and ImproMed, Inc.(R) Announce One-Click Home Delivery Integration 3
(Date:8/3/2015)... ... August 04, 2015 , ... Approved provider ... line up of live courses for the month of August. , Physical therapy ... individually or by purchasing a Physical Therapy Flex package. Flex packages allow therapists ...
(Date:8/3/2015)... ... August 03, 2015 , ... Sutter Health’s California Pacific Medical ... (COO) at CPMC. Hamila will start in her role effective immediately and will have ... has worked at CPMC and Sutter Health for about 15 years, including the past ...
(Date:8/3/2015)... ... August 03, 2015 , ... The Workgroup for Electronic Data ... IT to create efficiencies in healthcare information exchange, announced the release of its findings ... and Human Services (HHS) Secretary, WEDI shared survey results and recommendations ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... ruled in favor of the firm’s client Rebecca Hamsher, deciding that in accordance ... must reimburse benefits for Hamsher’s residential treatment for bulimia, depression and other mental ...
(Date:8/3/2015)... ... August 03, 2015 , ... A recent ... an overwhelming number of Hispanics believe people can positively affect their diabetes, few ... participants queried said making diet changes was important. Far fewer participants mentioned the ...
Breaking Medicine News(10 mins):Health News:Elite Online CE Provider Announces Schedule of Live Courses For Florida Physical Therapy Continuing Education 2Health News:Elite Online CE Provider Announces Schedule of Live Courses For Florida Physical Therapy Continuing Education 3Health News:Hamila Kownacki, RN Appointed as New Chief Operating Officer at CPMC 2Health News:WEDI ICD-10 Survey Results: Industry Nearing Readiness but Physician Practices Lagging Behind 2Health News:WEDI ICD-10 Survey Results: Industry Nearing Readiness but Physician Practices Lagging Behind 3Health News:WEDI ICD-10 Survey Results: Industry Nearing Readiness but Physician Practices Lagging Behind 4Health News:Kantor & Kantor Announces North Cypress Medical Center Must Reimburse Benefits for Mental Health Treatment 2Health News:Kantor & Kantor Announces North Cypress Medical Center Must Reimburse Benefits for Mental Health Treatment 3Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 2Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 3Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 4
... The National Patient Safety Foundation,(NPSF) today announced that ... leading health care solutions providers to work,alongside the ... their families -- all with the single convergent ... http://www.newscom.com/cgi-bin/prnh/20080307/AQF053LOGO ), "We are excited to be ...
... of Pennsylvania School of Medicine can now explain how ... in the blood stream at any one time. These ... fight infections. , "There is a steady state number ... says senior author Michael P. Cancro, PhD, Professor of ...
... with inflammatory diseases such as rheumatoid arthritis now have ... biologic disease-modifying antirheumatic drugs (DMARDs). These drugs, derived by ... of the disease rather than simply treating the symptoms. ... because a one month,s supply may cost 100 times ...
... Henri de Toulouse-Lautrec suffered, is a genetic disease characterized ... window into how joints are destroyed by arthritis. It ... cathepsin K which hampers osteoclasts (the cells that break ... poor bone resorption and dense, brittle bones. , ...
... Co-Pays, HOUSTON, Nov. 4 US Oncology today ... pharmacy, has,exceeded the $10 million mark in assisting more ... Care Advantage in August 2006., "It was important ... patient access to oral chemotherapies by easing the financial,burdens ...
... MYL ),today announced that its subsidiary Mylan ... and Drug Administration (FDA) for its,Abbreviated New Drug ... and 750 mg. Levetiracetam Tablets are the generic ... Mylan,s Vice Chairman and CEO, commented: "We are,extremely ...
Cached Medicine News:Health News:AmerisourceBergen Joins National Patient Safety Foundation Corporate Council 2Health News:Penn scientists show how body determines optimal amount of germ-fighting B cells 2Health News:Medicaid policies vary widely for rheumatoid arthritis drugs 2Health News:Genetic disorder sheds light on enzyme's role in bone metabolism 2Health News:OncologyRx Care Advantage(TM) Specialty Pharmacy Passes $10 Million Milestone in Patient Financial Assistance 2Health News:OncologyRx Care Advantage(TM) Specialty Pharmacy Passes $10 Million Milestone in Patient Financial Assistance 3Health News:Mylan Receives Final Approval for First-to-File Generic Version of Antiepileptic Keppra(R) and Launches Immediately 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: